Atossa Therapeutics
ATOS
14 hedge funds and large institutions have $471K invested in Atossa Therapeutics in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
0.03% more ownership
Funds ownership: 0.19% → 0.22% (+0.03%)
7% less funds holding
Funds holding: 15 → 14 (-1)
8% less capital invested
Capital invested by funds: $513K → $471K (-$42.1K)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$41K |
| 2 |
VF
Virtu Financial
New York
|
+$23K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$7.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$22K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$3K |
ATOS Hedge Fund Activity: Q4 2019 in Review
14 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2019, worth a combined $471K — down 8.2% from $513K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ATOS and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $41K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $22K sold.
- 14 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2019, down from 15 in Q3 2019.
- Funds reported $471K of Atossa Therapeutics stock for Q4 2019, down 8.2% quarter-over-quarter.
- 3 funds opened new Atossa Therapeutics positions in Q4 2019 and 4 closed out, a net change of -1 holder.
- The largest Atossa Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $41K added.
- The largest Atossa Therapeutics seller in Q4 2019 was JP Morgan Chase, an estimated $22K sold.
Based on aggregated 13F filings for Q4 2019.